Literature DB >> 21703421

Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition.

Philip Martin1, Yen-Nien Liu, Rachel Pierce, Wassim Abou-Kheir, Orla Casey, Victoria Seng, Daniel Camacho, R Mark Simpson, Kathleen Kelly.   

Abstract

Loss of PTEN and loss of TP53 are common genetic aberrations occurring in prostate cancer. PTEN and TP53 contribute to the regulation of self-renewal and differentiation in prostate progenitors, presumptive tumor initiating cells for prostate cancer. Here we characterize the transformed phenotypes resulting from deletion of the Pten and TP53 tumor suppressors in prostate epithelium. Using the PB-Cre4(+)Pten(fl/fl)TP53(fl/fl) model of prostate cancer, we describe the histological and metastatic properties of primary tumors, transplanted primary tumor cells, and clonal cell lines established from tumors. Adenocarcinoma was the major primary tumor type that developed, which progressed to lethal sarcomatoid carcinoma at approximately 6 months of age. In addition, basal carcinomas and prostatic urothelial carcinomas were observed. We show that tumor heterogeneity resulted, at least in part, from the transformation of multipotential progenitors. CK8+ luminal epithelial cells were capable of undergoing epithelial to mesenchymal transition in vivo to sarcomatoid carcinomas containing osseous metaplasia. Metastasis rarely was observed from primary tumors, but metastasis to lung and lymph nodes occurred frequently from orthotopic tumors initiated from a biphenotypic clonal cell line. Androgen deprivation influenced the differentiated phenotypes of metastases. These data show that one functional consequence of Pten/TP53 loss in prostate epithelium is lineage plasticity of transformed cells. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703421      PMCID: PMC3123810          DOI: 10.1016/j.ajpath.2011.03.035

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  30 in total

1.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

Authors:  L Bubendorf; A Schöpfer; U Wagner; G Sauter; H Moch; N Willi; T C Gasser; M J Mihatsch
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

2.  Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation.

Authors:  Yu-An Cao; Michael H Bachmann; Andreas Beilhack; Yang Yang; Masashi Tanaka; Rutger-Jan Swijnenburg; Robert Reeves; Cariel Taylor-Edwards; Stephan Schulz; Timothy C Doyle; C Garrison Fathman; Robert C Robbins; Leonore A Herzenberg; Robert S Negrin; Christopher H Contag
Journal:  Transplantation       Date:  2005-07-15       Impact factor: 4.939

3.  Expression of basal cell keratins in human prostate cancer metastases and cell lines.

Authors:  G J van Leenders; T W Aalders; C A Hulsbergen-van de Kaa; D J Ruiter; J A Schalken
Journal:  J Pathol       Date:  2001-12       Impact factor: 7.996

4.  p63 regulates commitment to the prostate cell lineage.

Authors:  Sabina Signoretti; Maira M Pires; Meghan Lindauer; James W Horner; Chiara Grisanzio; Sonya Dhar; Pradip Majumder; Frank McKeon; Philip W Kantoff; William R Sellers; Massimo Loda
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-28       Impact factor: 11.205

5.  Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.

Authors:  Rajal B Shah; Rohit Mehra; Arul M Chinnaiyan; Ronglai Shen; Debashis Ghosh; Ming Zhou; Gary R Macvicar; Soorynarayana Varambally; Jason Harwood; Tarek A Bismar; Robert Kim; Mark A Rubin; Kenneth J Pienta
Journal:  Cancer Res       Date:  2004-12-15       Impact factor: 12.701

6.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.

Authors:  Zhenbang Chen; Lloyd C Trotman; David Shaffer; Hui-Kuan Lin; Zohar A Dotan; Masaru Niki; Jason A Koutcher; Howard I Scher; Thomas Ludwig; William Gerald; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

7.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Authors:  Martine P Roudier; Lawrence D True; Celestia S Higano; Hubert Vesselle; William Ellis; Paul Lange; Robert L Vessella
Journal:  Hum Pathol       Date:  2003-07       Impact factor: 3.466

Review 8.  Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

Authors:  Scott B Shappell; George V Thomas; Richard L Roberts; Ron Herbert; Michael M Ittmann; Mark A Rubin; Peter A Humphrey; John P Sundberg; Nora Rozengurt; Roberto Barrios; Jerrold M Ward; Robert D Cardiff
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

9.  Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer.

Authors:  Shunyou Wang; Jing Gao; Qunying Lei; Nora Rozengurt; Colin Pritchard; Jing Jiao; George V Thomas; Gang Li; Pradip Roy-Burman; Peter S Nelson; Xin Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

10.  p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner.

Authors:  Alina Molchadsky; Igor Shats; Naomi Goldfinger; Meirav Pevsner-Fischer; Melissa Olson; Ariel Rinon; Eldad Tzahor; Guillermina Lozano; Dov Zipori; Rachel Sarig; Varda Rotter
Journal:  PLoS One       Date:  2008-11-12       Impact factor: 3.240

View more
  45 in total

1.  MiR-1 and miR-200 inhibit EMT via Slug-dependent and tumorigenesis via Slug-independent mechanisms.

Authors:  Y-N Liu; J J Yin; W Abou-Kheir; P G Hynes; O M Casey; L Fang; M Yi; R M Stephens; V Seng; H Sheppard-Tillman; P Martin; K Kelly
Journal:  Oncogene       Date:  2012-02-27       Impact factor: 9.867

Review 2.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

3.  Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.

Authors:  Miodrag Dragoj; Jasna Bankovic; Evangelia Sereti; Sofija Jovanovic Stojanov; Konstantinos Dimas; Milica Pesic; Tijana Stankovic
Journal:  Invest New Drugs       Date:  2017-07-22       Impact factor: 3.850

4.  Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Authors:  Akash Patnaik; Kenneth D Swanson; Eva Csizmadia; Aniruddh Solanki; Natalie Landon-Brace; Marina P Gehring; Katja Helenius; Brian M Olson; Athalia R Pyzer; Lily C Wang; Olivier Elemento; Jesse Novak; Thomas B Thornley; John M Asara; Laleh Montaser; Joshua J Timmons; Todd M Morgan; Yugang Wang; Elena Levantini; John G Clohessy; Kathleen Kelly; Pier Paolo Pandolfi; Jacalyn M Rosenblatt; David E Avigan; Huihui Ye; Jeffrey M Karp; Sabina Signoretti; Steven P Balk; Lewis C Cantley
Journal:  Cancer Discov       Date:  2017-03-08       Impact factor: 39.397

5.  TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer.

Authors:  Alexandra M Blee; Yundong He; Yinhui Yang; Zhenqing Ye; Yuqian Yan; Yunqian Pan; Tao Ma; Joseph Dugdale; Emily Kuehn; Manish Kohli; Rafael Jimenez; Yu Chen; Wanhai Xu; Liguo Wang; Haojie Huang
Journal:  Clin Cancer Res       Date:  2018-05-29       Impact factor: 12.531

Review 6.  Molecular pathogenesis and progression of prostate cancer.

Authors:  Randy Schrecengost; Karen E Knudsen
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

7.  Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.

Authors:  Arun K Nalla; Theodore F Williams; Casey P Collins; Dustin T Rae; Grant D Trobridge
Journal:  Mol Carcinog       Date:  2015-10-29       Impact factor: 4.784

Review 8.  Cancer stem cell plasticity and tumor hierarchy.

Authors:  Marina Carla Cabrera; Robert E Hollingsworth; Elaine M Hurt
Journal:  World J Stem Cells       Date:  2015-01-26       Impact factor: 5.326

9.  Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition.

Authors:  Yen-Nien Liu; Wassim Abou-Kheir; Juan Juan Yin; Lei Fang; Paul Hynes; Orla Casey; Dong Hu; Yong Wan; Victoria Seng; Heather Sheppard-Tillman; Philip Martin; Kathleen Kelly
Journal:  Mol Cell Biol       Date:  2011-12-27       Impact factor: 4.272

10.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.